No Data Available
Tissue Therapies Limited (TIS)
is a publicly listed company on the Australian Securities Exchange (ASX).
About Tissue Therapies Limited
Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.
Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology.
The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.
Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.
Tissue Therapies is currently focused on launching VitroGro® ECM in Europe and preparing the way for entering the USA and rest of world markets. In addition, the company is driven to expand its product line by exploring additional indications (use) of VitroGro® ECM while developing new intellectual property and new products.
They see opportunities to have significant impact in wound care markets in Asia, Australia, Canada, Europe, New Zealand, the United States and other markets experiencing the economic burden of wound care. They are also continuing to work with their research and development partners to create more effective, complimentary products for wound care and tissue repair.
Tissue Therapies Limited:
- Has exceptional clinical trial data and entered into a commercial partnership with Quintiles for sales of VitroGro® ECM in Europe.
- Is proceeding with regulatory approvals and reimbursement approvals in the Company's name.
- Has successfully completed commercial scale GMP manufacturing and has realised inventory in readiness for sale.
- Is proceeding with development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.
VitroGro® ECM is a sterile, acellular biomimetic scaffold for the treatment of hard-to-heal wounds, primarily venous leg ulcers. VitroGro® ECM replaces degraded wound matrix. VitroGro® ECM binds to a prepared wound bed and provides a scaffold for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as, cell proliferation and migration. VitroGro® ECM improves wound closure and reduces pain thereby improving wound care.
Chronic, hard to heal wounds are characterised by prolonged inflammation that degrades ECM components and senescent skin cells with a reduced capacity to maintain the balance of the ECM.
VitroGro® ECM replaces the degraded ECM in a chronic wound bed by forming a physical surface matrix by adsorption to damaged ECM in the wound bed. VitroGro® ECM is designed to be sticky to assist with adherence to the wound bed. Adhesion of skin cells in the wound to a functional ECM is a primary requirement for subsequent cell functions critical to wound healing, such as proliferation, migration, cell survival, and synthesis of new ECM. If cell attachment does not occur, these functions are not possible. The scaffold provided by VitroGro® ECM is a structure for cellular attachment and proliferation, leading to regeneration of the body's natural ECM. Newly attached cells in the wound bed subsequently produce new native ECM, which in turn, serves to guide normal tissue renewal, maturation and thereby restore healing.
Tissue Therapies Limited
179 Turbot Street
+61 7 3334 3900
Fax: +61 7 3334 3999
The General Overview, Services, Products and Projects information for this profile was last edited on 18 Mar 2015.